Asylia Therapeutics is a private development stage biotechnology company committed to transforming scientific advances into safe and effective medicines for cancer and auto-immune diseases. Asylia’s platform centers on a drug pipeline capable of modulating antigen presentation to the immune system which has produced unprecedented anti-tumor responses across multiple cancer models.
Asylia Therapeutics is a private development stage biotechnology company committed to transforming scientific advances into safe and effective medicines for cancer and auto-immune diseases. Asylia’s platform centers on a drug pipeline capable of modulating antigen presentation to the immune system which has produced unprecedented anti-tumor responses across multiple cancer models.
Asylia is led by a seasoned team of entrepreneurs, scientific leaders in immunity, oncology and clinical trials, and biotech executives with experience in antibody drug and business development.